45 terminated. 45 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Terminated 45 |
| Phase 1 | 5 | Terminated 5 |
| Phase 3 | 2 | Terminated 2 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis Dupilumab, Placebo, IBI356 - Atopic Dermatitis | Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 18 | 2025-12-31 | 2026-10-27 |
| A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) Dupilumab, JNJ-95475939, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 256 | 2025-02-26 | 2026-07-31 |
| Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 79 | 2024-06-05 | 2026-06-16 |
| A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 161 | 2023-11-16 | 2026-06-03 |
| Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis SAR444656 (KT-474), Placebo - Atopic Dermatitis | Phase 2 | Terminated | Sanofi | 70 | 2023-11-09 | 2026-11-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis LY3454738, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Eli Lilly and Company | 234 | 2023-06-21 | 2025-12-02 |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | Pfizer | 58 | 2023-01-18 | 2025-05-08 |
| A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis BMX-010, Placebo - Atopic Dermatitis | Phase 2 | Terminated | BioMimetix JV, LLC | 103 | 2023-01-08 | 2024-04-18 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis AK002, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Allakos Inc. | 131 | 2022-06-27 | 2024-10-15 |
| Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation Application of Tralokinumab - Atopic Dermatitis | Phase 2 / Phase 3 | Terminated | University of Zurich | 24 | 2022-06-15 | 2026-02-06 |
| An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis RPT193, Placebo - Atopic Dermatitis | Phase 2 | Terminated | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 229 | 2022-06-07 | 2026-03-23 |
| A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials EDP1815 - Atopic Dermatitis | Phase 2 | Terminated | Evelo Biosciences, Inc. | 287 | 2022-06-06 | 2023-09-07 |
| Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD Broncho-Vaxom, Placebo - Atopic Dermatitis | Phase 2 | Terminated | OM Pharma SA | 63 | 2021-12-20 | 2023-08-08 |
| Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel DBI-001, Aqueous gel - Atopic Dermatitis | Phase 2 | Terminated | DermBiont, Inc. | 10 | 2021-10-06 | 2023-11-08 |
| Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Placebo, AK120 - Atopic Dermatitis | Phase 2 | Terminated | Akesobio Australia Pty Ltd | 79 | 2021-09-30 | 2025-02-26 |
| A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Bermekimab, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 6 | 2021-09-02 | 2023-05-24 |
| Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study FB-401 - Atopic Dermatitis | Phase 2 | Terminated | Forte Biosciences, Inc. | 36 | 2021-06-02 | 2021-10-28 |
| A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Placebo, Bermekimab, Dupilumab - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 199 | 2021-05-03 | 2023-03-01 |
| A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) AR100DP1 - Dermatitis, Atopic | Phase 1 / Phase 2 | Terminated | Arjil Pharmaceuticals LLC | 17 | 2020-12-08 | 2023-12-11 |
Showing 20 of 45. Sign in to see all of them.
Eczema (13) · Dermatitis (8) · Immune System Diseases (4) · Pruritus (4) · Skin Diseases (4) · Lymphoma, Follicular (3) · Psoriasis (2) · Alopecia (1) · Inflammation (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Skin Diseases, Eczematous (1) · Staphylococcal Infections (1) · Striae Distensae (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (45) · Genetic Diseases, Inborn (45) · Hypersensitivity (45) · Hypersensitivity, Immediate (45) · Skin Diseases, Genetic (45) · Skin and Connective Tissue Diseases (45) · Skin Diseases, Eczematous (44) · Immune System Diseases (41) · Skin Diseases (41) · Dermatitis (37) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (5) · Skin Manifestations (5) · Hemic and Lymphatic Diseases (4) · Immunoproliferative Disorders (4)
dupilumab (4) · GSK1070806 (2) · bermekimab (2) · itepekimab (2) · 8,11,14-Eicosatrienoic Acid (1) · AK002 (1) · BANG polymer gel (1) · Broncho-Vaxom (1) · Clobetasol (1) · Oils (1) · Therapeutics (1) · antroquinonol (1) · benralizumab (1) · etrasimod (1) · gusacitinib (1)
GlaxoSmithKline (3) · Janssen Research & Development, LLC (3) · Regeneron Pharmaceuticals (3) · DermBiont, Inc. (2) · Eli Lilly and Company (2) · Lakefront Biotherapeutics NV (2) · Novartis Pharmaceuticals (2) · Akesobio Australia Pty Ltd (1) · Allakos Inc. (1) · Amgen (1) · Arjil Pharmaceuticals LLC (1) · Asana BioSciences (1) · AstraZeneca (1) · BioMAS Ltd (1) · BioMimetix JV, LLC (1)
United States (32) · Poland (18) · Canada (17) · Germany (17) · Japan (12) · Czechia (9) · Spain (9) · South Korea (7) · Hungary (6) · United Kingdom (6) · Argentina (5) · Australia (5) · France (5) · Taiwan (5) · Bulgaria (4)
Alex Zvulunov, Prof (1) · Avner Shemer, Prof (1) · Ben Ehst, PhD (1) · Chin Lee, MD, MPH (1) · Daisy Blanco, MD (1) · Dalia Gilat, Dr. (1) · David Zammit, Ph.D. (1) · Douglas Maslin, MD (1) · Eli Sprecher, Prof (1) · Emma Guttman, MD, PhD (1)
2018 (5), 2023 (3), 2017 (1)